Skip to main content

Marina Tarrés Mercader

Institutions of which they are part

Research technician
Gene Therapy at Nervous System
Vall Hebron Institut de Recerca

Marina Tarrés Mercader

Institutions of which they are part

Research technician
Gene Therapy at Nervous System
Vall Hebron Institut de Recerca

Projects

ESTUDIO Y DESARROLLO DE LA PRIMERA PLATAFORMA TECNOLÓGICA DE ENSAYOS PARA VIRUS ADENOASOCIADOS EN TERÁPIA GÉNICA

IP: Miguel Chillon Rodriguez
Collaborators: Susana Miravet Delgado, Laia Rubio Ortega, Marina Tarrés Mercader, Almudena Sanchez Garcia
Funding agency: Instituto de Salud Carlos III
Funding: 296571
Reference: PMPTA22/00048
Duration: 01/01/2023 - 30/06/2025

Related news

The European Rare Diseases Research Alliance (ERDERA) kicked off this September, with an estimated budget of 380 million euros and the aim of improving the lives of 30 million rare disease patients in Europe and beyond.

This gene therapy protects mice against cognitive deficits associated with aging, improves motor function, and delays the onset of diseases such as amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease.

Over the course of two days, experts presented the latest advances in vectors, different gene modification techniques and their transfer to clinical practice.

Related professionals

Eniruqe Alberto Vargas Meouchi

Eniruqe Alberto Vargas Meouchi

Research technician
Reconstructive Surgery of the Locomotor System
Read more
Gustavo Gimenez

Gustavo Gimenez

Predoctoral researcher
Infectious Diseases
Read more
Andrés Bustos Mardones

Andrés Bustos Mardones

Predoctoral researcher
Reconstructive Surgery of the Locomotor System
Read more
Berta Paez Montserrat

Berta Paez Montserrat

Predoctoral researcher
Neurovascular Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.